Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus BETA HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus BETA HC.
ARAZLO vs BETA-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Topical: Apply 0.045% gel once daily to affected areas of the face.
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid